2021 ICD-10-CM Diagnosis Code C94.20

Acute megakaryoblastic leukemia not having achieved remission

    2016 2017 2018 2019 2020 2021 Billable/Specific Code
  • C94.20 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • Short description: Acute megakaryoblastic leukemia not achieve remission
  • The 2021 edition of ICD-10-CM C94.20 became effective on October 1, 2020.
  • This is the American ICD-10-CM version of C94.20 - other international versions of ICD-10 C94.20 may differ.
Applicable To
  • Acute megakaryoblastic leukemia with failed remission
  • Acute megakaryoblastic leukemia NOS
The following code(s) above C94.20 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C94.20:
  • C00-D49
    2021 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C81-C96
    2021 ICD-10-CM Range C81-C96

    Malignant neoplasms of lymphoid, hematopoietic and related tissue

    Type 2 Excludes
    • Kaposi's sarcoma of lymph nodes (C46.3)
    • secondary and unspecified neoplasm of lymph nodes (C77.-)
    • secondary neoplasm of bone marrow (C79.52)
    • secondary neoplasm of spleen (C78.89)
    Malignant neoplasms of lymphoid, hematopoietic and related tissue
  • C94
    ICD-10-CM Diagnosis Code C94

    Other leukemias of specified cell type

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • leukemic reticuloendotheliosis (C91.4-)
    • myelodysplastic syndromes (D46.-)
    • personal history of leukemia (Z85.6)
    • plasma cell leukemia (C90.1-)
    Other leukemias of specified cell type
  • C94.2
    ICD-10-CM Diagnosis Code C94.2

    Acute megakaryoblastic leukemia

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    Applicable To
    • Acute myeloid leukemia M7
    • Acute megakaryocytic leukemia
    Acute megakaryoblastic leukemia
Approximate Synonyms
  • Acute megakaryoblastic leukemia
  • Leukemia, acute megakaryoblastic, fab m7
Clinical Information
  • A progressive, proliferative disease of blood cells, originating from immature megakaryocytes.
  • An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. Myelofibrosis or increased bone marrow reticulin is common.
  • An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. The prognosis is usually poor. (who, 2001)
ICD-10-CM C94.20 is grouped within Diagnostic Related Group(s) (MS-DRG v38.0):
  • 820 Lymphoma and leukemia with major o.r. Procedures with mcc
  • 821 Lymphoma and leukemia with major o.r. Procedures with cc
  • 822 Lymphoma and leukemia with major o.r. Procedures without cc/mcc
  • 823 Lymphoma and non-acute leukemia with other procedures with mcc
  • 824 Lymphoma and non-acute leukemia with other procedures with cc
  • 825 Lymphoma and non-acute leukemia with other procedures without cc/mcc
  • 840 Lymphoma and non-acute leukemia with mcc
  • 841 Lymphoma and non-acute leukemia with cc
  • 842 Lymphoma and non-acute leukemia without cc/mcc

Convert C94.20 to ICD-9-CM

Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
ICD-10-CM Codes Adjacent To C94.20
C93.9 Monocytic leukemia, unspecified
C93.90 …… not having achieved remission
C93.91 …… in remission
C93.92 …… in relapse
C94 Other leukemias of specified cell type
C94.0 Acute erythroid leukemia
C94.00 …… not having achieved remission
C94.01 …… in remission
C94.02 …… in relapse
C94.2 Acute megakaryoblastic leukemia
C94.20 …… not having achieved remission
C94.21 …… in remission
C94.22 …… in relapse
C94.3 Mast cell leukemia
C94.30 …… not having achieved remission
C94.31 …… in remission
C94.32 …… in relapse
C94.4 Acute panmyelosis with myelofibrosis
C94.40 …… not having achieved remission
C94.41 …… in remission
C94.42 …… in relapse

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.